Shulman DeMeo Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.97M Buy
1,641
+7
+0.4% +$7.15K 0.37% 24
2026
Q1
$1.5M Sell
1,634
-28
-2% -$28.4K 0.32% 27
2025
Q4
$1.79M Sell
1,662
-68
-4% -$65K 0.4% 21
2025
Q3
$1.32M Sell
1,730
-65
-4% -$48.4K 0.3% 24
2025
Q2
$1.4M Sell
1,795
-106
-6% -$82.4K 0.35% 21
2025
Q1
$1.57M Sell
1,901
-1
-0.1% -$832 0.44% 19
2024
Q4
$1.47M Sell
1,902
-28
-1% -$23.2K 0.4% 20
2024
Q3
$1.71M Sell
1,930
-57
-3% -$51.2K 0.42% 19
2024
Q2
$1.8M Sell
1,987
-10
-0.5% -$8K 0.47% 18
2024
Q1
$1.55M Sell
1,997
-12
-0.6% -$8.54K 0.41% 19
2023
Q4
$1.17M Sell
2,009
-46
-2% -$26.9K 0.33% 26
2023
Q3
$1.1M Sell
2,055
-43
-2% -$22.2K 0.37% 26
2023
Q2
$984K Sell
2,098
-111
-5% -$46.5K 0.29% 31
2023
Q1
$758K Sell
2,209
-17
-0.8% -$5.73K 0.24% 38
2022
Q4
$814K Buy
2,226
+2
+0.1% +$709 0.27% 36
2022
Q3
$719K Sell
2,224
-2
-0.1% -$634 0.26% 37
2022
Q2
$722K Sell
2,226
-70
-3% -$21K 0.24% 42
2022
Q1
$657K Buy
2,296
+139
+6% +$35.8K 0.18% 55
2021
Q4
$596K Buy
2,157
+156
+8% +$39.5K 0.16% 57
2021
Q3
$462K Buy
+2,001
New +$494K 0.4% 44
2021
Q2
Sell
-1,944
Closed -$363K 108
2021
Q1
$363K Buy
1,944
+349
+22% +$68.3K 0.1% 96
2020
Q4
$269K Buy
+1,595
New +$238K 0.08% 112

Other funds holding LLY

Shulman DeMeo Asset Management's LLY Position: Q2 2026 in Review

Shulman DeMeo Asset Management increased its Eli Lilly (LLY) stake by 0.43% in Q2 2026, buying an estimated $7.15K and bringing the position to 1,641 shares worth $1.97M. The position accounts for 0.37% of the portfolio, ranked #24.

Shulman DeMeo Asset Management first reported a position in LLY in Q4 2020 and has held it in 22 quarters since. 2,000 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Shulman DeMeo Asset Management held 1,641 shares of Eli Lilly worth $1.97M as of Q2 2026.
  • Shulman DeMeo Asset Management bought 7 Eli Lilly shares in Q2 2026, an estimated $7.15K.
  • Eli Lilly made up 0.37% of Shulman DeMeo Asset Management's portfolio in Q2 2026, its #24 holding.
  • Shulman DeMeo Asset Management first reported a position in Eli Lilly in Q4 2020 and has held it in 22 quarters since.
  • 2,000 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Shulman DeMeo Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.